Assessment of Bone Health Biomarker (ALP) after Treatment with Biofield Energy Treated DMEM in MG-63 Cells

Mahendra Kumar Trivedi¹* and Snehasis Jana²

Received: February 07, 2019;   Published:February 15, 2019

DOI: 10.32474/OSMOAJ.2019.02.000145

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

The aim was to examine the effect of Biofield Treated DMEM on bone health in MG-63 cells. Dulbecco’s Modified Eagle’s Medium was used as a test sample in this study and divided into two parts. First part received Biofield Treatment by Mahendra Kumar Trivedi and was labeled as the one-time Biofield Energy Treated (BT-I) DMEM, while the second part received two-times Biofield Treatment and denoted as BT-II. MTT assay was studied for cell viability, which was found as more than 73.9% in MG-63 cell line, which indicated with a safe and non-toxic profile. The bone health parameter, the level of ALP was significantly (p≤0.001) increased by 42.86% in both BT-I and BT-II groups compared with the untreated DMEM group. Thus, the data suggested that the Biofield Treated DMEM significantly improved ALP level, which can be used for the management of osteoporosis, deformed bones, bone and/or joint pain, rickets, osteoma, osteomalacia, aging, hormonal imbalance, and stress.

Keywords: Biofield Energy; ALP; Osteoporosis; Osteosarcoma Cells; DMEM; Bone Health

Abbreviations: NCCAM: National Center for Complementary and Alternative Medicine; ALP: Alkaline phosphatase; MG-63: Human Bone Osteosarcoma Cells; CAM: Complementary and Alternative Medicine; FBS: Fetal Bovine Serum; DMEM: Dulbecco’s Modified Eagle’s Medium

Abstract| Introduction| Material and Methods| Results and Discussion| Conclusion| Acknowledgement| References|